Abstract 30P
Background
Colorectal cancer (CRC) stands as a formidable contributor to cancer-related mortality globally, motivating ongoing efforts to enhance diagnostic and therapeutic strategies. Among emerging candidates, Suppressor of Cytokine Signalling 6 (SOCS6) has garnered attention for its potential implications in tumorigenesis, including CRC. Previously, dot blot technique revealed that SOCS6 binds to multiple candidates, including the erythropoietin receptor (EPOR), which is known to have role in cancer development. Therefore, SOCS6 could regulate the expression of EPOR to facilitate CRC progression. However, the differential expression patterns of SOCS6 and its correlation with EPOR in CRC is not well elucidated. This study aims to correlate expression levels of SOCS6 with the clinical outcomes using immunohistochemistry and to investigate the functional role of SOCS6 along with its correlation with EPOR in CRC.
Methods
Immunohistochemical staining was performed on a total of 80 formalin-fixed, paraffin-embedded CRC specimens, including 70 cancerous and 10 normal tissues, to unveil SOCS6 expression patterns. Moreover, to investigate the role, SOCS6 was silenced using siRNA and functional assays (cell proliferation, and wound healing) were performed in CRC cell lines (HT-29 and COLO-320DM). Also, qRT-PCR, and western blot were conducted to determine the correlation between SOCS6 and EPOR.
Results
Immunohistochemistry revealed a reduction in SOCS6 expression in CRC specimens compared to the normal tissue, yet not significantly associated with tumour stage or grade. Molecular investigations elucidated significant increase in cell proliferation in SOCS6 silenced HT-29 and COLO-320DM cells, demonstrating its tumor suppressive function. In terms of wound healing assay, the gap closure was significantly higher only in SOCS6 silenced COLO-320DM cells. In addition, silencing SOCS6 resulted in the upregulation of EPOR in COLO-320DM cells, however EPOR levels were reduced in HT-29 cells.
Conclusions
Our current findings suggest the tumour suppressive role of SOCS6 in CRC, with the potential to serve as a diagnostic and therapeutic marker.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Sultan Qaboos University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract